Synthesis, Optimization, and Structure–Activity Relationships of Imidazo[1,2-<i>a</i>]pyrimidines as Inhibitors of Group 2 Influenza A Viruses
作者:Saad Alqarni、Laura Cooper、Jazmin Galvan Achi、Ryan Bott、Veeresh Kumar Sali、Andrew Brown、Bernard D. Santarsiero、Aleksej Krunic、Balaji Manicassamy、Norton P. Peet、Pin Zhang、Gregory R. J. Thatcher、Irina N. Gaisina、Lijun Rong、Terry W. Moore
DOI:10.1021/acs.jmedchem.2c01329
日期:2022.10.27
develop novel anti-influenza therapies. Here, we present a novel imidazo[1,2-a]pyrimidine scaffold that targets group 2 IAV entry. We have explored three different regions of the lead compound, and we have developed a series of small molecules that have nanomolar activity against oseltamivir-sensitive and -resistant forms of group 2 IAVs. These small molecules target hemagglutinin (HA), which mediates
甲型流感病毒(IAV)是一种传染性很强的病毒,可引起大流行和季节性流行,这是重大的公共卫生问题。目前的抗流感治疗受到限制,部分原因是耐药 IAV 菌株的不断出现;因此,开发新型抗流感疗法的需求尚未得到满足。在这里,我们提出了一种新颖的咪唑并 [1,2- a]靶向第 2 组 IAV 进入的嘧啶支架。我们探索了先导化合物的三个不同区域,并开发了一系列小分子,这些小分子对奥司他韦敏感和耐药形式的第 2 组 IAV 具有纳摩尔活性。这些小分子靶向介导病毒进入过程的血凝素 (HA)。用抗性突变体绘制 HA 结构的已知小分子结合空腔表明这些分子与该空腔结合并阻断 HA 介导的膜融合。